阿立哌唑治疗精神分裂症患者致锥体外系反应的危险因素  

The risk factors of side-effect of extrapyramidal system on the treatment of schizophrenia by aripiprazolein

作　　者：张云飞[1] 马长林[1] 葛旭峰 闻毅[1] 杨晓丽[1] 李华芳[2] ZHANG Yunfei;MA Changlin;GE Xufeng(Mental Health Center of Jiading District in Shanghai, Shanghai 201823,China)

机构地区：[1]上海市嘉定区精神卫生中心,上海201823 [2]上海交通大学医学院附属市精神卫生中心

出　　处：《国际精神病学杂志》2018年第3期459-461,共3页Journal Of International Psychiatry

摘　　要：目的探析阿立哌唑治疗精神分裂症后患者致锥体外系反应(EPS)的危险因素。方法选取80例精神分裂症患者,均予以阿立哌唑单药开放性治疗。观察总有效率与不良反应总发生率。根据患者治疗期间是否出现EPS将患者分为EPS组与非EPS组,比较两组一般资料、PANSS基线评分、剂量增加幅度、最小与最大剂量。多元线性回归分析探索EPS危险因素。结果患者治疗前的PANSS评分为(83.6±7.6)分,治疗后降至(41.5±5.2)分(P<0.05)。总有效率为82.3%(63/76),不良反应总发生率为28.9%(22/76),其中EPS发生率为15.8%(12/76)。EPS组PANSS基线评分、剂量增加幅度、最小剂量、最大剂量均高于非EPS组(P<0.05)。PANSS基线评分、剂量增加幅度、最大剂量为EPS危险因素(P<0.05)。结论阿立哌唑治疗精神分裂症的疗效良好,PANSS基线评分、剂量增加幅度与最大剂量为阿立哌唑治疗精神分裂症后患者致EPS的危险因素,值得引起重视。Objective To investigate the risk factors of side-effect of extrapyramidal system on the treatment of schizophrenia by aripiprazolein. Methods 80 patients with schizophrenia were selected and treated with aripiprazole monotherapy. The total effective rate and the total incidence of adverse reactions were observed. Patients were divided into EPS group and non-EPS group. The general information, PANSS score on baseline, increase rate of dose, minimum dose, maximum dose were compared between two groups. Parallel multivariate linear regression analysis was made to explore the risk factors. Results Before treatment, The PANSS score was 83.6 ± 7.6 and it decreased to 41.6 ± 5.2 after treatment The total effective rate was 82.3 % （63/76）, the incidence of adverse events was 28.9 % （22/76）, and the incidence of EPS was 15.8 % （ 12/76 ） . The PANSS baseline score, increase rate of dose, the minimum dose and the maximum dose of aripiprazolein in EPS group were significantly higher than those in the non-EPS group （P 〈0.05 ） . Conclusion Aripiprazole is effective in the treatment of schizophrenia. The PANSS baseline score, the increase rate of dose and the maximum dose of aripiprazole were the risk factors of EPS in the treatment of schizophrenia by aripiprazolein.

关 键 词：精神分裂症 阿立哌唑 锥体外系反应 危险因素 

分 类 号：R971.41[医药卫生—药品]